5 Key Takeaways

• 1

  The ASPECT trial indicates that combining low-dose atropine with DIMS lenses enhances myopia control compared to atropine alone.

• 2

  At 12 months, axial elongation was significantly lower in the combination therapy group (0.07 mm) compared to the atropine-only group (0.18 mm).

• 3

  Nearly 40% of children receiving combination therapy showed no axial elongation, compared to 12% in the control group.

• 4

  The study suggests that achieving near-physiological axial growth could reduce the lifetime risk of myopia-related complications.

• 5

  Tolerability of the combination therapy was good, although adherence to the regimen remains a challenge for patients.